SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs1128503

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 3 clinical trials

Clinical Trials


1 Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events

Vitamin K antagonists were hampered by several disadvantages, such as the need for frequent monitoring. In this context, new oral anticoagulants (NOACs) have been developed and are now available on the market. These NOACs, like all anticoagulant drugs, continue to be associated with an increased risk of bleeding. In addition, the lack of antidote and the absence of valid data regarding biological monitoring can pose problems in case of overdose or when emergency surgery is required. Studies investigating the pharmacokinetic properties of rivaroxaban and dabigatran, two NOACs now approved for the market, have shown high variability between individuals, with coefficients of variation of up to 60% for some pharmacokinetic parameters in patients treated after orthopaedic surgery. The relation between plasma concentrations of NOAC and bleeding risk has been clearly established in clinical trials. Dabigtran, rivaroxaban and apixaban are known substrates of P-glycoprotein (Pgp). Pgp activity can be affected by pharmacological inducing or inhibiting agents. This can lead to a significant change in the pharmacokinetics of NOACs, with a decrease or increase (respectively) in the level of intestinal absorption, leading to respectively reduced or increased plasma concentrations of the drug. Furthermore, there exist genetic mutations of Pgp, presenting in particular a lower level of activity than the non-mutated protein. We hypothesized that the polymorphisms (mutations) of the ABCB1 gene that codes for Pgp could influence plasma concentrations of dabigatran, rivaroxaban and apixaban, and consequently, impact on the concentration of NOACs and as a corollary, on the bleeding and thromboembolic risk of patients treated with these molecules. The main objective of this study is to study the relation between polymorphisms of the ABCB1 gene that codes for Pgp and plasma concentrations of NOACs in patients treated for a hemorrhagic or thromboembolic complication occurring under NOAC therapy. Secondary objectives are to evaluate the distribution of ABCB1 polymorphisms among the various hemorrhagic risk factors, and to compare the frequency of the polymorphism in patients from the study population vs the general population.

NCT02103101 Anticoagulants Thromboembolism Hemorrhage Other: Measurement of Plasma Concentrations of NOACs Genetic: Identification of ABCB1 polymorphisms coding for P-gp
MeSH:Thromboembolism Hemorrhage
HPO:Thromboembolism

To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).. Inclusion Criteria: - Patients aged >18 and <80 years of age - Patients admitted to the University Hospital of Besancon for a serious adverse event (major bleeding complication or thrombo-embolic event) occurring under treatment with any one of the three commercially available new oral anticoagulant agents (rivaroxaban, apixaban or dabigatran).

Primary Outcomes

Description: Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.

Measure: Measurement of plasma concentrations of new oral anticoagulant agents

Time: 0 days (at inclusion)

Description: To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).

Measure: Identification of polymorphisms of the gene ABCB1 coding for P-gp

Time: 0 days (at inclusion)

2 TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol (TACTIC) Trial

Breast cancer patients undergoing trastuzumab-based HER2-directed therapy are at risk of heart function decline or heart failure symptoms, but it is unknown if, when, and for how long cardiovascular protective strategies, e.g. with a beta-blocker, could help. This study randomly assigns those taking curative-intent trastuzumab-based HER2-directed therapy to the beta-blocker carvedilol—either when significant heart function decline or subtle early signs of heart injury (either by elevation of a cardiac blood biomarker, i.e. cardiac troponin, or by an abnormal heart ultrasound marker, i.e. global longitudinal strain) are noted, or preventatively before beginning trastuzumab-based HER2-directed therapy. This study will further randomly assign those patients on carvedilol to either discontinuation at the end of trastuzumab-based HER2-directed therapy or continuation for another year, providing much needed clinical trial data on what the best strategy ("tactic") for those at risk of cardiotoxicity with trastuzumab-based HER2-directed therapy is.

NCT03879629 Breast Cancer Drug: Carvedilol
MeSH:Cardiomyopathies
HPO:Cardiomyopathy

Correlation of absolute delta change in GLS and LVEF while on trastuzumab and after stopping trastuzumab with the frequency of the following SNPs: trastuzumab-related: p<1x10-5 hits from Norton GWAS (six loci) 130 HER 2 Ile665Val, HER2 Pro1170Ala125, 126, 130, anthracycline-related: ABCB1 rs1128503, ABCB4 rs1149222, ABCC1 rs45511401, ABCC2 res17222723, CAT rs10836235, CBR3 rs1056892, CYBA rs4673, CYP3A4*22 rs35599367, NCF4 rs1883112, RAC2 rs13058338, RARG rs2229774, SLC28A3 rs7853758, TOP2B rs10865801, and UGT 1A6*4 rs1786378374, 150-152, beta-blocker-related: β2-AR Gln27Gln, β1-AR Arg389Arg 80-82 and CYP2D6 polymorphisms (CYP2D6 alleles (*1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *15, *17, *19, *20, *29, *35, *36, *40 and *41), as well as 7 CYP2D6 gene duplications (*1 9 N, *2 9 N, *4 9 N, *10 9 N, *17 9 N, *35 9 N and *41 9 N) by use of the AmpliChip CYP450 GeneChip.

Primary Outcomes

Description: Incidence of heart failure or asymptomatic decline in left-ventricular ejection fraction (LVEF) by >10% in patients whose LVEF is ≥50% or LVEF drop ≥5% in those with a decrease to <50% (primary outcome measure)

Measure: Rate of asymptomatic and symptomatic cardiac dysfunction

Time: 1 year

Description: Reversible LVEF decline to within 5% of baseline (secondary primary outcome measure)

Measure: Rate of reversible cardiac function decline

Time: 1 year

Secondary Outcomes

Description: Delta change in LVEF from completion to one year after completion of trastuzumab-based HER2-directed therapy

Measure: Cardiac function changes after completion of HER2-directed therapy

Time: 1 year

Description: Correlation of absolute delta change in GLS and LVEF while on trastuzumab and after stopping trastuzumab with the frequency of the following SNPs: trastuzumab-related: p<1x10-5 hits from Norton GWAS (six loci) 130 HER 2 Ile665Val, HER2 Pro1170Ala125, 126, 130, anthracycline-related: ABCB1 rs1128503, ABCB4 rs1149222, ABCC1 rs45511401, ABCC2 res17222723, CAT rs10836235, CBR3 rs1056892, CYBA rs4673, CYP3A4*22 rs35599367, NCF4 rs1883112, RAC2 rs13058338, RARG rs2229774, SLC28A3 rs7853758, TOP2B rs10865801, and UGT 1A6*4 rs1786378374, 150-152, beta-blocker-related: β2-AR Gln27Gln, β1-AR Arg389Arg 80-82 and CYP2D6 polymorphisms (CYP2D6 alleles (*1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *15, *17, *19, *20, *29, *35, *36, *40 and *41), as well as 7 CYP2D6 gene duplications (*1 9 N, *2 9 N, *4 9 N, *10 9 N, *17 9 N, *35 9 N and *41 9 N) by use of the AmpliChip CYP450 GeneChip

Measure: Gene variants and risk of cardiotoxicity and response to therapy

Time: 2 years

3 Federal Cardiomonitoring System. Determination of the Efficiency of a Single-lead ECG Recorded With CardioQVARK Cardiac Monitor in Order to Detect Atrial Fibrillation in Primary Health Centers.

This interventional prospective multicenter nonrandomized clinical and epidemiological study is the first Russian study aimed at evaluating the effectiveness of a single-lead electrocardiography device (CardioQVARK) in screening for atrial fibrillation in primary health care.

NCT04204330 Atrial Fibrillation Device: CardioQvark cardiac monitor and software, single-lead ECG
MeSH:Atrial Fibrillation
HPO:Atrial fibrillation Paroxysmal atrial fibrillation

For new oral anticoagulants - rs2244613 of the gene CES1, rs1045642 (C3435T), rs1128503 (C1236T), rs2032582 (G2677T / А) of the gene ABCB1, rs2231142 (С421А, Q141K) of the gene ABCG2, rs776746 (A6986G * 399 CYP3 CYP3) CYP3A4.. Inclusion Criteria: Men and women aged 18 to 96 years who have one or more of the following risk factors: - hypertonic disease - history of ischemic stroke or transient ischemic attacks - type 1 and type 2 diabetes - 1-3 degrees obesity - heart failure or the presence of a clinic to reduce exercise tolerance associated with shortness of breath - coronary heart disease or the presence of symptoms of chest pain, in the absence of an established diagnosis of coronary heart disease - the presence of peripheral arterial atherosclerosis - the presence of a clinic of interruptions in the work of the heart (bouts of rapid, irregular heartbeats, pauses in work of heart) Non-inclusion criteria: - Acute coronary syndrome - Acute ischemic or hemorrhagic stroke - Acute psychosis - The presence of severe concomitant diseases with an expected life expectancy of less than 2 years Exclusion Criteria: Refusal of further participation in the study Inclusion Criteria: Men and women aged 18 to 96 years who have one or more of the following risk factors: - hypertonic disease - history of ischemic stroke or transient ischemic attacks - type 1 and type 2 diabetes - 1-3 degrees obesity - heart failure or the presence of a clinic to reduce exercise tolerance associated with shortness of breath - coronary heart disease or the presence of symptoms of chest pain, in the absence of an established diagnosis of coronary heart disease - the presence of peripheral arterial atherosclerosis - the presence of a clinic of interruptions in the work of the heart (bouts of rapid, irregular heartbeats, pauses in work of heart) Non-inclusion criteria: - Acute coronary syndrome - Acute ischemic or hemorrhagic stroke - Acute psychosis - The presence of severe concomitant diseases with an expected life expectancy of less than 2 years Exclusion Criteria: Refusal of further participation in the study Atrial Fibrillation Atrial Fibrillation This is an interventional, prospective, multicenter, nonrandomized clinical and epidemiological study.

Primary Outcomes

Description: Total number of AF cases newly diagnosed during the study period.

Measure: Total number of AF cases newly diagnosed during the study period.

Time: Through study completion, an average of 1 year

Description: Number of patients who, for the first time ever, were assigned to anticoagulation therapy.

Measure: Number of patients who, for the first time ever, were assigned to anticoagulation therapy.

Time: Through study completion, an average of 1 year

Description: Assessed using data obtained from pharmacokinetic analysis. International normalised ratio (INR) - target range from 2 to 3.

Measure: Compliance to anticoagulation therapy for warfarin.

Time: 6 months after administration of anticoagulants

Description: Assessed using data obtained from pharmacokinetic analysis. Quantitative determination of the concentration of drugs in the blood (blood sampling three hours after taking the drug).

Measure: Compliance to anticoagulation therapy for new oral anticoagulants.

Time: 6 months after administration of anticoagulants

Description: Evaluated as incremental cost-effectiveness ratio of screening per quality adjusted life year gained, and per stroke avoided.

Measure: Cost-effectiveness of using the single-lead CardioQVARK ECG device in screening for AF in primary health care.

Time: Through study completion, an average of 1 year

Secondary Outcomes

Description: Mean time to diagnosis.

Measure: Mean time to diagnosis.

Time: Through study completion, an average of 1 year

Description: Number of patients with a CHA₂DS₂-VASc score (the CHA2DS2-VASc Score is the most commonly utilized method to predict thromboembolic risk in atrial fibrillation) of ≥ 1.

Measure: Number of patients with a CHA₂DS₂-VASc score (the CHA2DS2-VASc Score is the most commonly utilized method to predict thromboembolic risk in atrial fibrillation) of ≥ 1.

Time: Through study completion, an average of 1 year

Description: Number of patients with a CHA₂DS₂-VASc score (the CHA2DS2-VASc Score is the most commonly utilized method to predict thromboembolic risk in atrial fibrillation) of ≥ 2.

Measure: Number of patients with a CHA₂DS₂-VASc score (the CHA2DS2-VASc Score is the most commonly utilized method to predict thromboembolic risk in atrial fibrillation) of ≥ 2.

Time: Through study completion, an average of 1 year

Description: Defined as frequency of ischemic stroke or transient ischemic attack in patients with newly diagnosed AF and assigned anticoagulants.

Measure: Incidence of ischemic stroke or transient ischemic attack after enrollment in the study.

Time: Through study completion, an average of 1 year

Description: Defined as frequency of massive hemorrhage in patients with newly diagnosed AF and assigned anticoagulants.

Measure: Incidence of massive hemorrhage after enrollment in the study.

Time: Through study completion, an average of 1 year

Description: Defined as frequency of hemorrhagic stroke in patients with newly diagnosed AF and assigned anticoagulants.

Measure: Incidence of hemorrhagic stroke after enrollment in the study.

Time: Through study completion, an average of 1 year

Description: For warfarin - CYP2C9 (CYP2C9 * 2, CYP2C9 * 3), VKORC1 (1 marker), CYP4F2 (1 marker), GGCX (1 marker). For new oral anticoagulants - rs2244613 of the gene CES1, rs1045642 (C3435T), rs1128503 (C1236T), rs2032582 (G2677T / А) of the gene ABCB1, rs2231142 (С421А, Q141K) of the gene ABCG2, rs776746 (A6986G * 399 CYP3 CYP3) CYP3A4.

Measure: Pharmacogenetic testing by polymorphic markers

Time: 6 months after administration of anticoagulants


HPO Nodes


HP:0001638: Cardiomyopathy
Genes 716
NDUFS7 PEX5 PDGFRA LMNA TCAP TPM1 EPG5 SGCB DOLK GPC4 PCCB XK MLX CPT2 GPR101 VCL TAZ MAP2K2 YARS2 TWNK RRM2B SDHA MC2R TMPO BRAF PRKAG2 BSCL2 AHCY TNNC1 NEU1 XRCC4 IDUA VPS33A GABRD TRNL1 CAP2 MYO18B IDH2 NDUFA10 GYG1 VCL LAMC2 NDUFV2 SLC25A4 TNNI3K RNU4ATAC CHKB DES MYH7 JUP BAG3 PEX10 MYBPC3 HADHA TRNL1 CRYAB SLC2A10 LMNA RAF1 TMEM43 MYOT HADHA WFS1 MAP2K1 TACO1 HADHA MYH7 PPA2 ACTN2 HSD17B10 GPC4 PEX19 NDUFB11 MYLK2 COX10 SARDH NAGA TRNK MRPL3 ATP6 TMEM70 GMPPB ND1 DES MAP2K2 KLF1 POMT2 NDUFS1 CAV3 KRAS DPM3 HFE COX2 FASTKD2 PTPN11 ITPA ANK1 CDKN1C FKTN ACTA1 TK2 RYR1 BSCL2 RNASEH2A ATP5F1D SHOC2 SDHA NDUFS3 FHL1 ANO5 HNRNPA2B1 PARS2 PPCS NDUFA11 ND3 XRCC2 FOS TPM3 RBCK1 TNNT2 ELAC2 TRNQ ACTA1 COX6B1 NDUFB11 COL7A1 HRAS PALB2 NDUFB8 COX7B ABCC9 COX8A ND3 TGFB3 ACADS TMEM126B DSP LDB3 FANCE DES RMND1 HADHA PSEN2 NDUFS2 TTR NDUFS2 TRNS1 H19 ARSB LAMP2 SLC25A20 PTPN11 RAD51 ALMS1 RAF1 NDUFS2 TNNT2 FKTN TAZ POLG2 COQ4 NRAS RAF1 HNRNPA1 RAB3GAP2 SGCB ACTC1 SYNE1 MYH7 NF1 HACD1 MYL3 AGK POLG COX7B PEX7 FANCD2 SYNE2 SLC25A4 KCNJ8 GLA ANKRD11 FHL1 SYNE2 DSP TERT USP9X TPM2 LAMA3 NDUFA2 SDHA SDHB MRPS22 ND1 NAXD DMD FXN SPEG GNPTAB SHOC2 IDUA FKRP NDUFA12 NDUFAF4 BMP2 ND6 NNT COG7 ECHS1 GATAD1 FHL2 NDUFV2 LDB3 TOP3A ND2 SLC25A4 POMT1 ERCC4 HADHB PNPLA2 CSRP3 LAMA2 DLD MTFMT SUFU SCO2 VPS13A NEBL POMK FLNC RNF113A HMGCL MYH6 AGK TSFM MAP2K1 TNNI3 BRCA1 TRNS1 GATA4 MRPL44 FIG4 LAMA4 RFWD3 PCCA NDUFS2 PRKAG2 COX1 DTNA HPS1 DMD TNNT2 BRAF LMNA COL7A1 FXN LMNA NBAS TXNRD2 ND5 NDUFAF6 PEX14 ACADVL EMD ND4 WARS2 ANKS6 TMEM126A TREX1 GPC3 FKRP PKP2 ATAD3A NUP107 MEN1 LMNA CAV1 HADHB HGSNAT MMUT ELN PEX26 TGFB1 PMM2 FLNC H19-ICR NDUFA11 TWNK LDB3 PLN SLC19A3 SCN5A RAF1 FOXRED1 NEXN NDUFAF2 FANCC TPI1 HJV PET100 MAD2L2 SLC25A3 KBTBD13 ERCC2 NDUFB9 MMUT DOLK PPARG FOXRED1 NDUFS7 TRNV PLN PCCA TAPT1 COX14 SCN5A CSRP3 ACAD9 VCP KRAS RFC2 ERBB3 GTPBP3 ERCC3 GSN NDUFAF1 DSC2 LAMP2 TRNN NDUFV1 LMNA TXNRD2 PTPN11 MYL2 ND6 TRNT PET100 CPT1A FKTN ABCC9 XYLT1 HLA-B XYLT2 PEX3 COX15 DSG2 NDUFA10 DSG2 DPM3 SDHD TRNW TRNF JUP TPM2 OPA1 MICOS13 DNAJC19 NDUFA6 NDUFS1 PNPLA2 NAGA PHYH DNAJC19 PMM2 LMNA NDUFAF4 ACTA1 LAMA4 PRDM16 ND2 EYA4 MLYCD PPCS PEX6 PIGT CRYAB GNE NDUFAF1 MYBPC3 ALG1 SLC30A10 SKI NDUFAF3 TAZ TTN KCNAB2 ACADVL INSR SLC25A3 CPT2 BRAF AGPAT2 TNNI3 ENPP1 WFS1 CISD2 MYH7 COA8 SELENON POMT1 LIMK1 MRAP PRKAG2 SCO2 TBL2 PEX2 RIT1 MYSM1 UBE2T GJA5 USP8 ND4 LAMB3 TRNT1 TACO1 DMD RNASEH2B ACTN2 SPTB NDUFA9 TWNK CSRP3 FLAD1 AARS2 ATPAF2 EPG5 MTO1 SPTA1 FBXL4 RERE NDUFS4 SGCD TNNC1 LDB3 MAP3K20 JUP ABCC6 CPT2 GATA5 FAH NDUFS3 ACAD9 COX20 VCL ACAD8 GSN NDUFAF2 FANCL SDHA FKTN TWNK RRM2B GMPPB IFIH1 SOS1 SLC40A1 MYH7 FHL1 FOXRED1 PEX7 COX15 SURF1 TTN SELENON TRIP4 GMPPB DCAF8 KCNH1 NEK8 NDUFS6 TTN ACADL HADH NDUFAF3 POLG CLIP2 NDUFV1 BRIP1 SLC19A2 DSG2 TNNT2 KRAS BAG3 JUP GYS1 TNNI3 POMGNT1 IGF2 FANCF ANKRD1 COA6 ADCY5 TMEM126B LIAS EYA4 PCCB ACTC1 GNS ACTA1 HAMP C1QBP DSP NDUFB11 ATAD3A ADCY5 BRAF ADAR GTF2E2 TIMMDC1 STAR FKRP CRYAB LMNA TPM2 CRYAB MYOZ2 NDUFAF5 SGSH ACAD8 TRNK RNASEH1 AGL TTR IDUA NDUFS8 CPT2 SLC25A20 NEXN ABHD5 RMRP COA5 KCNQ1 PEX7 ITGA7 COQ2 NDUFS8 ND1 FANCA NDUFA13 TRNL1 POMT1 NDUFS4 MYH7 SLC4A1 TMEM43 GTF2H5 FANCM TARS1 MYH6 CLN3 POLG DLD AHCY TPM3 GBE1 SDHAF1 PSEN1 MYL2 CDH23 BAG3 RAF1 NDUFB10 NDUFAF5 SGCA KAT6B MYH6 POLG UBR1 PEX13 MPLKIP TNNI3 PSEN1 MYBPC3 MGME1 NEB PEX11B SDHA TPM1 RBM20 LTBP4 ALMS1 COA8 HBB BBS2 POMT2 AIP PDHA1 MIB1 DSP ALG1 BRCA2 CENPE NDUFS4 ND5 HAMP NDUFB11 MYPN TTPA POMT1 RAD51C MGME1 GTF2I EPB42 TRNW PEX1 PPP1CB COX3 MYPN RNU4ATAC BCS1L FTO RNASEH2C MYPN LMNA TFR2 GUSB TMEM70 NDUFA4 SLX4 TRNH ATP6V1A D2HGDH NEXN GATAD1 PSEN2 NUP107 HFE GLB1 SCO1 NDUFA2 ATP6 HCCS TNNC1 NEB NAGLU AIP TRNS2 HRAS PIGT SGCD FANCG FANCI TTN SAMHD1 NUBPL PGM1 RBM20 ABCC9 MMP1 TANGO2 MRPS14 KCNQ1OT1 CAVIN1 PLN PPARG FIG4 LMNA MIPEP ACTC1 BAZ1B FHL1 DES MYH7 IL12B LMNA PRDM16 NDUFV2 ABCC6 SLC22A5 RYR2 ATP5F1E FANCB NDUFS8 MAP2K1 SDHAF1 GPC3 HADH HJV NPPA TPM3 KLHL41 MYPN AIP BOLA3 TRNE GTPBP3 DMD HCCS TCAP LIPT1 VAC14 SLC25A4 LIMS2 PEX16 DSP NDUFB3 JPH2 VPS33A SURF1 CLPB TNNI3 MYOT TAF1A PRDM16 TPM1 MYH6 POLG NDUFA1 GTF2IRD1 PEX12 SDHD DMD AGPAT2 TRNK SMC1A PHYH